The Courier & Advertiser (Fife Edition)
‘Fantastic’ boost as GSK invests £110m in Angus
Pharmaceutical giant’s investment a vote of confidence in Montrose
Tayside has been given a major boost with pharmaceutical giant GlaxoSmithKline investing £110 million in its Montrose operation.
The 460-job site is to receive a new facility for the manufacture of respiratory active ingredients.
Overall, GSK is spending a total of £275m at Montrose, County Durham and Hertfordshire, in a significant investment in its UK manufacturing network.
Les Thomson, director of GSK’s Montrose site, said: “The investment is fantastic news for the site, the staff and the local community.
“The commitment shown by GSK is a reflection of the quality and dedication of the people we have here as we look to create a further world-class manufacturing capability for many years to come.”
The new facility will replace an existing building that has manufactured respiratory active ingredients for more than 40 years.
The investment will provide longterm security for the manufacturingrelated roles and a continued supply of respiratory medicine to millions of patients around the world.
Chief executive Andrew Witty said: “The further investment supports our pharmaceutical pipeline and meets growing demand for our innovative portfolio of products.”
UK Government minister Andrew Dunlop said: “It is great news that GlaxoSmithKline is boosting investment in Scotland, and a real testament to the hard work and skills of the workforce in Montrose.”
Scottish business minister Paul Wheelhouse said: “Life sciences is a vital industry in Scotland, employing more than 35,000 people, and is a world leader.
“This success is built on our strong academic base and the cutting-edge research going on across Scotland.
“This latest investment demonstrates the continued confidence that international companies have in Scotland and our high-quality workforce.”
This investment is fantastic news for the site, the staff and the community